Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study
Authors' conclusion
Preemptive analgesia with DEX significantly improves both intraoperative nociceptive control as objectively measured by the NOX and postoperative pain control.
Study context
- Population
- Patients undergoing noncardiac surgery
- Participants
- 220 patients
- Comparison
- Preemptive IV dexmedetomidine vs placebo
- Dexmedetomidine (DEX)n = 108
- POn = 112reference
- Primary endpoint
- Co-primary: intraoperative NOX compliance rate (mean NOX ≤60 during nociceptive stimulation) and incidence of moderate-to-severe postoperative pain (pNRS > 3)
- Follow-up
- 0, 24, 48 hours, and 7 days (pain)
Methodological detailssingle-centre, double-blind, placebo-controlled
- Single-centre
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Intraoperative NOX compliance rate
P < 0.001
- NRS>3 significantly lower in DEX at all time points
- P = 0.000
Secondary outcomes
| Outcome | Z | P value |
|---|---|---|
| Rescue opioid consumptionReduced with DEX | −2.428 | P = 0.004 |
| mPONVDecreased with DEX | −4.901 | P = 0.001 |
Hemodynamic stability
- Improved with DEX
Safety
Safety events
- Safety profiles favorable in DEX group
Original publication
Dexmedetomidine Preemptive Analgesia on Intra- and Postoperative Pain in Noncardiac Surgery: A Randomized, Double-Blind, Controlled Study. Anesth Analg. Published 28 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →